Drug Trial Radar · NCT05138133
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
363
Actual
Start
Feb 15, 2022
Primary completion
Feb 23, 2027
Study completion Oct 4, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Conditions
- Lupus Nephritis
Interventions
AnifrolumabDrug
Anifrolumab intravenous infusion (IV)
PlaceboDrug
Placebo intravenous infusion (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in proportion of participants with CRR (Complete Renal Response) in anifrolumab group compared with placebo groupTime frame: Week 52
Locations
164 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Glendale, Arizona
Research Site
La Palma, California
Research Site
Los Angeles, California
Research Site
Upland, California
Research Site
Plantation, Florida
Research Site
Atlanta, Georgia
Research Site
Louisville, Kentucky
Research Site
Summit, New Jersey
Research Site
Manhasset, New York
Research Site
New York, New York
Research Site
Winston-Salem, North Carolina
Research Site
Middleburg Heights, Ohio
Research Site
Colleyville, Texas
Research Site
Edinburg, Texas
Research Site
El Paso, Texas
Research Site
Houston, Texas
Research Site
CABA, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
La Plata, Argentina
Research Site
Rosario, Argentina
Research Site
San Juan, Argentina
Research Site
Brussels, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Belo Horizonte, Brazil
Research Site
Campinas, Brazil
Research Site
Cuiabá, Brazil
Research Site
Maringá, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Recife, Brazil
Research Site
Salvador, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Bengbu, China
Showing 40 of 164 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.